Pelitrexol（Cat No.:I008630）is a folate antagonist primarily used in the treatment of various cancers and autoimmune diseases. It acts by inhibiting dihydrofolate reductase, an enzyme critical for the synthesis of nucleotides, thereby disrupting DNA replication and cell proliferation. Pelitrexol has shown efficacy in treating conditions such as leukemia and lymphoma, as well as in managing rheumatoid arthritis. Its mechanism of action allows for selective targeting of rapidly dividing cells, making it a valuable agent in chemotherapy. Ongoing research aims to better understand its full therapeutic potential and optimize its use in clinical settings.
| Catalog Number | I008630 |
| CAS Number | 446022-33-9 |
| Synonyms | AG 2037; Pelitrexol.;(S)-2-(5-(2-((S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)ethyl)-4-methylthiophene-2-carboxamido)pentanedioic acid |
| Molecular Formula | C20H25N5O6S |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid |
| InChI | InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1 |
| InChIKey | QXOPTIPQEVJERB-JQWIXIFHSA-N |
| SMILES | CC1=C(SC(=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@H]2CC3=C(NC2)N=C(NC3=O)N |
